Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODAC to review Amgen’s Nplate, ESAs

Executive Summary

FDA's Oncologic Drugs Advisory Committee will meet March 12-13 to review the cumulative data, including recent study results, on the risk of erythropoeisis-stimulating agents in patients with cancer and to consider the BLA for Amgen's platelet producer Nplate (romiplostim). Discussion regarding the safety of ESAs will focus on Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit as well as Roche's Mircera, FDA says in the Jan. 25 Federal Register. At the last ODAC review of ESA safety, the panel recommended that sponsors conduct additional trials to support continued marketing in the oncology setting (1"The Pink Sheet" May 14, 2007, p. 3)...

You may also be interested in...



EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials

Sponsors of erythropoiesis-stimulating agents should conduct additional safety studies to support continued marketing in the oncology setting, FDA's Oncologic Drugs Advisory Committee unanimously recommends

QUOTED. 27 January 2021. Scott Whitaker.

Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.

Korean Biopharma IPOs Start Strong With Prestige

Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel